



MAYNE PHARMA MARKET UPDATE

10 February 2025, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), provides a market update for the six months ended 31 December 2024 (1H FY25).

Mayne Pharma expects 1H FY25 revenues to be \$210 – \$215 million, reflecting 12 – 14% growth on 1H FY24. In addition, Mayne Pharma expects to report 1H FY25 underlying EBITDA¹ of \$30 – \$32 million representing growth of 275 – 300% on 1H FY24.

This underlying EBITDA result in 1H FY25 is driven by continued growth across the Women's Health portfolio with increased operating leverage. In addition, Dermatology saw improvement of margin primarily through product mix. The Company's performance since the update provided at the annual general meeting on 21 November 2024 (**AGM**) should be reflected across the entire half, and not assumed as a 2-month run rate going forward.

Looking forward to 2H FY25, the Company expects to see continued growth, some seasonal cost impacts from patient payment programs as deductibles reset, and an increase in promotional expenses for Women's Health products to drive additional growth.

Cash and marketable securities at 31 December 2024 was \$124.9 million, a decrease of \$4.6 million compared to the balance as of 31 October 2024 reported at the AGM, on timing of GTN payments.

Shawn Patrick O'Brien, CEO and Managing Director, Mayne Pharma said. "We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded particularly within our Women's Health segment. We look forward to further updating our investors on our progress and plans at the half year results presentation in late February."

The preliminary results for the six months ended 31 December 2024 are subject to finalisation of the auditor review process and Board approval. Full details of the 1H FY25 results together with a review of the Company's performance in 1H FY25 will be released on Wednesday, 26 February 2025.

Mayne Pharma's CEO Mr Shawn Patrick O'Brien and CFO Mr Aaron Gray will host a webcast of the results at 9.30am AEDT on Wednesday 26 February 2025. Participants can register for the webcast by navigating to <https://ccmediaframe.com/?id=jHfb8HeM>.

¹ Underlying Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) is a non-IFRS measure and excludes earn-out reassessments, restructuring charges, class action settlement costs, derivative fair value adjustments, litigation expense and certain capitalized earnouts

For personal use only





For further information contact:

Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board of Directors.

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40 year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Important information

This announcement contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward-looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan', 'target' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward-looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions; changes in the legal and regulatory regimes in which the Company operates; litigation or government investigations; decisions by regulatory authorities including approval of our products as well as their decisions on label claims; competitive developments affecting our products; changes in behaviour of major customers, suppliers and competitors; interruptions to manufacturing or distribution; acquisitions and divestitures; the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.